Korean J Neurotrauma.
2023 Sep;19(3):298-306. 10.13004/kjnt.2023.19.e42.
Anticoagulation and Antiplatelet Agent Resumption Timing fo
- Affiliations
-
- 1Department of Neurosurgery, Dankook University College of Medicine, Cheonan, Korea
- KMID: 2552593
- DOI: http://doi.org/10.13004/kjnt.2023.19.e42
Abstract
- Traumatic brain injury (TBI) is a major global health concern. Due to the increase in TBI incidence and the aging population, an increasing number of patients with TBI are taking antithrombotic agents for their underlying disease. When TBI occurs in patients with these diseases, there is a conflict between the disease, which requires an antithrombotic effect, and the neurosurgeon, who must minimize intracranial hemorrhage. Nevertheless, there are no clear guidelines for the reversal or resumption of antithrombotic agents when TBI occurs in patients taking antithrombotic agents. In this review article, we intend to classify antithrombotic agents and provide information on them. We also share previous studies on the reversal and resumption of antithrombotic agents in patients with TBI to help neurosurgeons in this dilemma.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Management of Peptic Ulcer Bleeding in Patients Taking Aspirin or Anticoagulant
- Discontinuation of Anticoagulant or Antiplatelet Therapy for Transrectal Ultrasound-Guided Prostate Biopsies: A Single-Center Experience
- Fatal Renal Bleeding in a Patient Treated With Aggressive Antithrombotic Therapy After Recurrent Coronary Stent Thrombosis
- Gastrointestinal endoscopy in anticoagulated patients: diagnosis and treatment
- The Effect of Preoperative Antiplatelet Therapy on Hemorrhagic Complications after Decompressive Craniectomy in Patients with Traumatic Brain Injury
